Wave Life Sciences
- Country
- 🇸🇬Singapore
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 268
- Market Cap
- $704.7M
- Introduction
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- Drug: WVE-006
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06405633
- Locations
- 🇨🇦
Inspiration Research Limited, Toronto, Ontario, Canada
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- Drug: WVE-006
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06186492
- Locations
- 🇬🇧
Simbec-Orion Clinical Pharmacology,, Merthyr Tydfil, Wales, United Kingdom
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
- Conditions
- FTDALS
- Interventions
- Drug: WVE-004
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05683860
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇳🇱Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇬🇧University of Oxford - Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom
Study of WVE-003 in Patients With Huntington's Disease
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT05032196
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇳🇱Maastricht University Medical Center, Maastricht, Netherlands
🇬🇧Cardiff University, Schools of Medicine and Biosciences, Cardiff, Wales, United Kingdom
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
- Conditions
- ALSFTD
- Interventions
- Drug: WVE-004Drug: Placebo
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT04931862
- Locations
- 🇦🇺
Perron Institute, Nedlands, Western Australia, Australia
🇳🇱Erasmus University MC, Rotterdam, Netherlands
🇨🇦McGill University Health Center - Research Institute, Montréal, Quebec, Canada
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT04906460
- Locations
- 🇯🇴
The Specialty Hospital (TSH)/ Advanced Clinical Center, Amman, Jordan
🇯🇴Istiklal Hospital/ Clinical Research Unit, Amman, Jordan
🇬🇧Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, United Kingdom
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
- Conditions
- Huntington Disease
- Interventions
- Drug: WVE-120102
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04617860
- Locations
- 🇦🇺
North Metropolitan Health Service, Perth, Western Australia, Australia
🇦🇺Alfred Health, Melbourne, Victoria, Australia
🇵🇱Instytut Psychiatrii i Neurologii, Warsaw, Poland
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
- Conditions
- Huntington Disease
- Interventions
- Drug: WVE-120101
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT04617847
- Locations
- 🇦🇺
Royal Brisbane & Women's Hospital, Herston, Queensland, Australia
🇦🇺Calvary Health Care Bethlehem, Parkdale, Victoria, Australia
🇫🇷Hospital Henri Mondor, Créteil, France
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: WVE-210201 (suvodirsen)Drug: Placebo
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03907072
- Locations
- 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇫🇷Hôpitaux Universitaires de Strasbourg, Strasbourg, Bas-Rhin, France
🇫🇷Hôpital Des Enfants, Toulouse, Haute-Garonne, France
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: WVE-210201Drug: Placebo
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03508947
- Locations
- 🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
🇧🇪CHR de la Citadelle, Liège, Belgium
🇺🇸Rare Disease Research, LLC., Atlanta, Georgia, United States